Henry Schein (NASDAQ:HSIC) Given New $92.00 Price Target at JPMorgan Chase & Co.

Henry Schein (NASDAQ:HSIC) had its target price upped by analysts at JPMorgan Chase & Co. from $78.00 to $92.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 12.35% from the stock’s current price.

HSIC has been the topic of a number of other reports. Mizuho raised their target price on shares of Henry Schein from $81.00 to $88.00 and gave the company a “neutral” rating in a research note on Wednesday. Barclays initiated coverage on shares of Henry Schein in a research note on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target for the company. Wells Fargo & Company raised their price objective on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, Evercore increased their target price on Henry Schein from $83.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $82.67.

Henry Schein Price Performance

NASDAQ:HSIC traded down $1.46 during trading hours on Wednesday, hitting $81.89. 1,082,759 shares of the company’s stock traded hands, compared to its average volume of 1,384,953. Henry Schein has a 52 week low of $60.56 and a 52 week high of $89.29. The business’s fifty day simple moving average is $77.56 and its two-hundred day simple moving average is $71.90. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The firm has a market cap of $9.64 billion, a P/E ratio of 25.90, a P/E/G ratio of 2.40 and a beta of 0.88.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 14.76% and a net margin of 3.02%.The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.34 billion. During the same period in the prior year, the company earned $1.19 EPS. The company’s quarterly revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. On average, research analysts anticipate that Henry Schein will post 4.74 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Henry Schein

Several institutional investors and hedge funds have recently bought and sold shares of HSIC. CYBER HORNET ETFs LLC purchased a new position in Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc purchased a new position in shares of Henry Schein in the second quarter worth $27,000. Flagship Harbor Advisors LLC purchased a new stake in Henry Schein during the 4th quarter valued at $30,000. Federated Hermes Inc. bought a new stake in Henry Schein in the 4th quarter worth $32,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Henry Schein in the fourth quarter valued at about $37,000. 96.62% of the stock is currently owned by institutional investors.

Henry Schein News Summary

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 results beat expectations — EPS $1.34 vs. $1.30 est., revenue $3.44B vs. $3.34B; revenue grew ~7.7% year/year, driven by dental and medical equipment strength. Reuters: Henry Schein beats quarterly profit estimates
• Positive Sentiment: FY2026 guidance roughly in line or slightly above Street: EPS guide 5.230–5.370 (consensus ~5.280) and revenue guide $13.6B–$13.8B (above ~$13.5B consensus) — supports continued revenue growth expectations. Press Release / Slide Deck
• Positive Sentiment: Multiple analyst upgrades/price-target raises after results: Robert W. Baird upgraded to Outperform with a $100 PT; Wells Fargo and Leerink raised targets to $87. These increases signal incremental analyst confidence in the recovery story. Benzinga / The Fly
• Neutral Sentiment: Market reaction earlier pushed shares to a 52-week high as investors digested the beat and guidance. Coverage and call transcripts are available for detailed read-through of management’s commentary. Benzinga: 52-week high
• Neutral Sentiment: Earnings call and transcripts note strategic wins and product strength but are mixed on timing of margin recovery — useful for longer-term thesis but not an immediate catalyst. Seeking Alpha: Q4 earnings call transcript
• Negative Sentiment: Margin pressure highlighted by analysts and some coverage: gross/margin contraction in the quarter tempers the upside from sales growth and is cited as a reason for cautious ratings. Zacks: Margins down
• Negative Sentiment: Bearish analyst stance persists: Morgan Stanley/Morgan analyst maintained a Sell/Underweight view with a ~$58–61 PT (well below current levels), keeping downside risk if margins or execution disappoint. TipRanks: Sell rating maintained

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.